SAN ANTONIO -- Surgically menopausal women with hypoactive sexual desire disorder experienced significant relief when wearing both an estrogen and a testosterone patch in a placebo-controlled trial.
"This is the first study to evaluate the efficacy of a testosterone patch used in combination with an estrogen patch, rather than oral estrogen, which is metabolized quite differently," said Dr. Susan Davis, principal investigator of the trial, sponsored by Procter & Gamble, which markets a testosterone patch.
"What was really striking about our results is that we had an extremely low placebo response. And, additionally, the psychological well-being and mood of the subjects improved," Dr. Davis said at the annual meeting of the American Society for Reproductive Medicine.
No androgen replacement therapy is currently approved in the United States for women.
The 24-week randomized, double-blind, multicenter trial was conducted in Europe and Australia. A total of 77 surgically menopausal women were randomized to treatment with a testosterone patch (300 [micro]g/day) or a placebo patch. Women in both groups also wore an estrogen patch. Sexual desire was measured using the Profile of Female Sexual Function (PFSF), said Dr. Davis, director of research at the Jean Hailes Foundation in Victoria, Australia.
Women in the testosterone group experienced an average increase of 75% in their sexual desire scores over the course of the study. …